Key Findings From Recent Trials

Basic Trazodone Information

• INN (International Nonproprietary Name): Trazodone
• Brand Names Available In United States: Desyrel; Oleptro (extended-release, US withdrawn); other international brands available worldwide; see Drugs.com/International for full listing
• ATC Code: N06AX05
• Forms & Dosages: Immediate-release tablets 50 mg and 100 mg; extended-release tablets 75 mg, 100 mg, 150 mg (marked CR/XR/retard); prolonged-release tablets 75 mg and 150 mg; oral solution not typically marketed
• Manufacturers In United States: not specified
• Registration Status In United States: FDA approved for Major Depressive Disorder (MDD); check FDA and local agency listings for current labeling
• OTC / Rx Classification: Prescription only (Rx) in all markets

What recent trials tell patients and prescribers about trazodone.

Randomized studies and meta-analyses from 2022–2026 focused mainly on two clinical questions: low-dose trazodone for insomnia and extended-release trazodone for major depressive disorder.

Across trials, low bedtime doses (25–100 mg) consistently shortened sleep latency and improved sleep continuity.

At antidepressant doses, moderate efficacy was reported at 75–150 mg/day, with incremental benefits seen up to 400 mg/day in treatment‑resistant cases.

Extended‑release formulations were designed to preserve antidepressant effect while reducing morning sedation.

Head‑to‑head trials showed small tolerability differences between IR and XR formulations, with no major efficacy gaps.

Safety patterns remained stable across studies.

Common adverse events were sedation, dizziness with orthostatic hypotension, and anticholinergic‑like effects.

Rare but serious events reported in pharmacovigilance include priapism, QT prolongation/arrhythmias, SIADH/hyponatremia, and serotonin syndrome.

Regulators such as the FDA and EMA continue to use approval for MDD as the anchor for trial design.

Limitations in the evidence base include heterogeneous dosing, mixed patient populations, and sparse pediatric data.

Practical takeaway: trazodone has the strongest evidence as a sedating antidepressant useful for comorbid insomnia and MDD when patients are monitored for orthostatic effects and rare serious adverse events.

Major 2022–2026 Studies

Which studies mattered most for clinicians and patients.

Recent randomized trials targeted low-dose bedtime regimens to treat insomnia and compared immediate‑release with extended‑release formulations in MDD.

Large meta‑analyses pooled small randomized trials and observational data to assess sleep outcomes and antidepressant response rates.

Trials often used sleep latency and sleep continuity as primary endpoints for insomnia studies.

MDD trials commonly used standard depression rating scales and 6–12 week endpoints.

Enrollment tended to include adults with comorbid insomnia and depression, with fewer trials focused on primary insomnia alone.

Main Outcomes

What patients can expect in symptom improvement.

Low doses at bedtime (25–100 mg) showed reliable hypnotic effects within nights to a few days.

Improvements included reduced time to fall asleep and fewer awakenings, improving subjective sleep quality.

Antidepressant effects appear at 75–150 mg/day with measurable benefit by 2–4 weeks.

For refractory depression, up‑titration to 300–400 mg/day produced additional benefit in some patients under close supervision.

Extended‑release products maintained mood benefits with somewhat lower reports of morning grogginess in many trials.

Safety Observations

Key safety points drawn from trials and pharmacovigilance.

Most common adverse events were sedation and dizziness related to alpha‑1 blockade and H1 antagonism.

Orthostatic hypotension and falls are important concerns in elderly patients.

Rare serious events—priapism, prolonged QT/arrhythmia, serotonin syndrome with polypharmacy, and hyponatremia/SIADH—continue to appear in safety databases.

Extended‑release formulations attempt to reduce morning sedation but do not eliminate other class‑related risks.

Clinical Mechanism Of Action

How does trazodone help mood and sleep in plain language?

Layman’s Explanation

Trazodone is an antidepressant that helps both mood and sleep by enhancing serotonin signaling and blocking certain serotonin receptors that disrupt sleep.

At low doses it mainly causes sedation and helps people fall and stay asleep.

At higher doses it provides fuller antidepressant action.

Scientific Breakdown

What the pharmacology tells clinicians.

Trazodone is classified under ATC code N06AX05 as an "other antidepressant."

Its principal mechanisms are serotonin reuptake inhibition and antagonism at 5‑HT2A and 5‑HT2C receptors.

Secondary receptor effects include antagonism at histamine H1 and alpha‑1 adrenergic receptors, which explains sedation and orthostatic hypotension.

Modest inhibition of the serotonin transporter (SERT) contributes to antidepressant effects with a side‑effect profile distinct from many SSRIs in certain patients.

Receptor Pharmacology

Which receptors matter for clinical effects.

5‑HT2A and 5‑HT2C blockade improves sleep continuity and can reduce anxiety and agitation.

H1 antagonism causes sedation and explains the reliable hypnotic benefit at low doses.

Alpha‑1 antagonism produces dizziness and orthostatic hypotension, which should be monitored especially in older adults.

Pharmacokinetics (Overview)

How formulations change effect and tolerability.

Immediate‑release tablets (commonly 50–100 mg) are absorbed rapidly and often cause pronounced first‑dose sedation when taken at bedtime.

Extended‑release or prolonged‑release forms (75–150 mg marked CR/XR/retard) aim to produce steadier plasma levels and reduce morning grogginess.

Clinical implication: dose determines primary use—low doses (25–100 mg at bedtime) for sleep and higher daily doses (75–400 mg/day divided) for antidepressant action.

Scope Of Approved & Off-Label Use

What is trazodone officially approved for, and how do clinicians actually use it?

United States Approvals

Trazodone is approved by major agencies including the FDA and EMA for the treatment of major depressive disorder.

Marketed brands include Desyrel worldwide and various regional names internationally.

Oleptro was an extended‑release product available in North America but has had changes to market availability.

Prescription status applies in all markets, and product monographs list approved strengths and safety information.

Notable Off-Label Trends

How clinicians commonly prescribe trazodone beyond the label.

The dominant off‑label use is insomnia, with clinicians frequently prescribing 25–100 mg at bedtime for short‑term relief.

Other off‑label uses include adjunctive anxiety treatment, behavioral disturbances in dementia (used cautiously), chronic pain adjunct, and PTSD‑related sleep disturbance.

Immediate‑release tablets are often used for sleep onset, while extended‑release forms are chosen when daytime tolerability or adherence is the priority.

Pediatric use is generally not recommended because safety and efficacy are not established.

Elderly patients typically start low, for example 50 mg at bedtime, with close monitoring for orthostasis and falls.

Dosage Strategy

How should trazodone be started and adjusted safely?

General Dosing

Begin low and titrate to clinical response while monitoring sedation and orthostatic symptoms.

For adults with MDD the usual starting regimen is 75–150 mg/day in divided doses.

Therapeutic effect is assessed at 2–4 weeks and doses increased as tolerated.

Common maximum outpatient doses are up to 400 mg/day; inpatient supervised doses may reach 600 mg/day in select cases.

Condition-Specific Dosing

MDD: Start at about 75 mg/day divided, and increase every several days toward 150–300 mg/day if tolerated.

Evaluate response at 2–4 weeks and continue at least six months after remission.

Insomnia (off‑label): Single nightly dose 25–100 mg at bedtime, typically short‑term; reassess frequently.

Elderly and hepatic/renal impairment: Start lower and titrate more slowly due to potential accumulation and increased sensitivity.

Pediatric: Not established; avoid except under specialist advice.

Missed doses: Take when remembered unless near the next dose; do not double up.

Overdose: Seek urgent care for drowsiness, arrhythmias, respiratory depression, seizures, or priapism.

Safety Protocols

What to screen for before prescribing and how to follow patients.

Contraindications

Absolute contraindications include known hypersensitivity to trazodone or excipients.

Other contraindications are recent myocardial infarction and acute intoxication with alcohol, hypnotics, or other central nervous system depressants.

Adverse Effects

Common adverse events: sedation/drowsiness, dizziness or lightheadedness from orthostatic hypotension, headache, dry mouth, nausea, blurred vision, constipation, and fatigue.

Serious but rare events: priapism (urological emergency), arrhythmias and QT prolongation, serotonin syndrome when combined with other serotonergic drugs, and hyponatremia due to SIADH—especially in older patients.

Monitoring recommendations: baseline cardiovascular assessment if arrhythmia risk exists, orthostatic vitals after dose changes, and sodium checks for high‑risk patients.

Counsel patients to avoid alcohol and CNS depressants and to report prolonged erections, severe dizziness, or confusing symptoms immediately.

Interaction Mapping

Which foods and drugs change trazodone’s safety or effectiveness?

Food Interactions

No major food restrictions are required for absorption.

Avoid alcohol and other CNS depressants because combined use increases sedation and respiratory depression risk.

Taking trazodone at bedtime uses its sedative effect to therapeutic advantage and reduces daytime impairment.

Drug Combinations To Avoid

Avoid MAO inhibitors because of serotonin syndrome risk.

Use caution with other potent serotonergic agents (SSRIs, SNRIs, triptans, linezolid, certain opioids) to reduce the risk of serotonin toxicity.

Exercise caution with drugs that prolong QT interval and in patients with cardiac disease because trazodone can contribute to arrhythmia risk.

Potent CYP3A4 inhibitors or inducers may change trazodone exposure; monitor clinical effects and consider dose adjustments.

Alpha‑1 blockade may potentiate orthostatic hypotension when combined with antihypertensive medications.

Always review prescription, over‑the‑counter, and herbal products for interactions before starting trazodone.

Patient Experience Analysis

What do patients say about trazodone in surveys and online forums?

Survey Data

Aggregated surveys show three dominant patient experiences: reliable sleep induction at low doses, daytime sedation or morning grogginess on initiation or with higher doses, and mood improvement over weeks when used at antidepressant doses.

Tolerability is generally acceptable, and many patients prefer trazodone when insomnia coexists with depression because it addresses both problems.

Forum Trends

Online communities often praise trazodone for sleep but report concerns about prolonged drowsiness, vivid dreams, and occasional sexual side effects.

Rare reports of priapism appear in forums and emphasize the importance of urgent medical attention for that event.

Discontinuation stories commonly stress the need for gradual tapering to avoid rebound insomnia or withdrawal symptoms.

Clear counseling on onset of benefit—sleep effects often within nights and antidepressant effects in 2–4 weeks—improves adherence and safety reporting.

Distribution & Pricing Landscape

How available is trazodone and what does it cost?

Trazodone is widely marketed in Europe, the Americas, and parts of Asia under brands such as Desyrel, Trittico, Donaren, Trazonil, and Trazolan.

Major suppliers and manufacturers include Angelini Group, Intas Pharma, Mylan, Gonane, Global Pharma Tek, Shandong Octagon, TAPI, and Fermion among others.

As an off‑patent drug available as generic and branded generics, trazodone is generally low‑cost compared with newer antidepressants.

Extended‑release formulations often carry higher prices than immediate‑release generics.

Formulary placement, supplier selection, and local regulatory registration affect availability and pricing in clinics and pharmacies.

In our online pharmacy, trazodone is available without a prescription, with discreet delivery to United States in 5-14 days.

Alternative Options

Which drugs should clinicians consider when trazodone is not suitable?

Comparison Table

• SSRIs (sertraline, escitalopram, fluoxetine): Strong antidepressant efficacy, less sedating, sexual side effects more common.
• Mirtazapine: Sedating at low doses with appetite stimulation; weight gain is a common trade‑off.
• Doxepin (low dose): Approved for sleep maintenance but has anticholinergic risk in elderly patients.
• Nefazodone: Similar SARI class but rare hepatotoxicity limits use.

Pros And Cons

Trazodone Pros: dual utility for sleep and mood, low abuse potential, widely available generics, cost‑effective.

Trazodone Cons: daytime sedation, orthostatic hypotension, rare serious events such as priapism and arrhythmia, limited pediatric data.

Clinical choice should be driven by the primary symptom profile, cardiac risk, polypharmacy, and patient preference.

When insomnia predominates, low‑dose trazodone or low‑dose doxepin may be selected.

For primary depression without sleep complaints, SSRIs or SNRIs are often first‑line.

Regulatory Status

Where trazodone stands with regulators worldwide.

Trazodone (INN) is approved and registered in multiple jurisdictions for major depressive disorder, with FDA and EMA listing the drug as an approved antidepressant.

Registrations and brand names vary by country; Trittico and related brands are listed across many European markets.

The drug is not scheduled as a controlled substance and carries low abuse potential.

Formulations include IR tablets 50/100 mg and extended‑release tablets 75–150 mg; labeling varies by product and country.

Clinicians should consult local drug agency databases and product monographs for current approval and packaging information.

Consolidated FAQ

Common Patient Questions Answered

Is trazodone approved for sleep?

Not widely approved specifically for insomnia; sleep is a common off‑label use and typical bedtime doses are 25–100 mg.

What brands and dosages exist?

Immediate‑release tablets commonly 50 and 100 mg; extended‑release/prolonged‑release tablets in 75–150 mg strengths; brands include Desyrel and many regional generics.

How fast does it work?

Sleep benefit is often seen within nights; antidepressant effects typically take 2–4 weeks.

What are serious risks?

Priapism, arrhythmias/QT prolongation, hyponatremia, and serotonin syndrome are rare but serious and require urgent care.

Can I stop suddenly?

No; taper gradually to reduce withdrawal and rebound insomnia.

Is it safe for elderly or kids?

Elderly: start low (often 50 mg at bedtime) and monitor for orthostatic hypotension and sedation.

Pediatric: safety and efficacy are not established; avoid unless under specialist supervision.

How should trazodone be stored?

Store at room temperature 15–30°C (59–86°F), in the original packaging, protected from moisture and light.

Visual Guide

What graphics help patients and clinicians understand trazodone quickly?

Suggested Visuals For Articles Or Patient Handouts

Schematic mechanism image showing SERT inhibition plus 5‑HT2 antagonism with downstream sleep and mood effects.

Dosing timeline infographic differentiating low‑dose bedtime use (25–100 mg) for sleep versus antidepressant dosing (75–400 mg/day divided).

Side‑effect severity heatmap prioritizing common versus rare serious adverse events.

Quick-Reference Dosing Flowchart

Start → Assess Indication (Insomnia vs MDD) → Choose Formulation (IR vs XR) → Starting Dose (25–100 mg bedtime for sleep; 75 mg/day divided for MDD) → Monitor 1–4 Weeks → Titrate Or Switch.

Safety Monitoring Checklist

Baseline vitals and orthostatics.

Cardiac history and ECG if arrhythmia risk exists.

Serum sodium checks for high‑risk patients.

Patient education on priapism and serotonin syndrome signs.

Avoid alcohol and CNS depressants.

Storage & Transport

How to keep trazodone stable and safe during storage and shipping.

Store trazodone at room temperature 15–30°C (59–86°F) in original packaging protected from moisture and light.

Solid oral dosage forms are generally stable under normal ambient shipping conditions, but protect from prolonged heat and humidity.

Pharmacies should label bottles with storage temperatures and advise patients not to store medication in bathrooms where humidity is high.

Unused medication should be returned to take‑back programs where available.

Guidelines For Proper Use

How to start, monitor, and stop trazodone safely.

Initiation And Titration

Choose dosing based on the indication—insomnia 25–100 mg at bedtime, MDD starting at 75 mg/day divided.

Titrate every few days as tolerated for antidepressant dosing; evaluate response at 2–4 weeks.

Elderly and patients with hepatic or renal impairment require slower titration and lower starting doses.

Consider extended‑release formulations when daytime sedation or adherence is a concern.

Monitoring And Discontinuation

Baseline medical history should include cardiac disease, glaucoma, seizure risk, and current medications.

Monitor for sedation, orthostatic hypotension, GI side effects, and rare serious signs such as priapism or syncope.

Order ECG or sodium testing when clinically indicated rather than routinely.

Taper gradually when discontinuing to minimize withdrawal symptoms and rebound insomnia.

If a dose is missed, take as soon as remembered unless close to the next dose; do not double doses.

Delivery Across United States

Consolidated FAQ

Quick answers for common concerns collected from earlier sections.

Is trazodone a controlled substance?

No; it is not scheduled and has low abuse potential.

How should trazodone be taken for sleep?

Short‑term bedtime dosing of 25–100 mg is commonly used off‑label for insomnia.

What should be watched for in elderly patients?

Start at low doses, monitor for orthostatic hypotension and sedation, and consider periodic sodium checks when appropriate.

When is ECG or sodium monitoring indicated?

Obtain ECG if there are cardiac risk factors or QT‑prolonging co‑medications; check sodium in elderly or patients on diuretics or at risk for SIADH.

Final Notes

Trazodone remains a versatile option in the antidepressant toolkit when insomnia coexists with depression.

Its pharmacology—serotonin reuptake inhibition plus 5‑HT2 antagonism—explains both hypnotic and mood benefits.

Choose dosing according to the primary complaint, start low, titrate slowly, and monitor for orthostasis and rare but serious adverse events.

When prescribing, reconcile all medications to avoid serotonergic interactions and drugs that prolong QT interval.

Clinicians should consult product labels and local agency guidance for the most current regulatory and formulation information.